Need Help?

ICGC Oesophageal adenocarcinoma - tumour samples

The oesophageal project will focus on adenocarcinoma which is increasing in incidence in the UK and other developed countries and has a very poor outcome. The primary aims of this project are to deeply sequence tumour and normal genomic DNA (including the precursor condition Barrett’s oesophagus when material is available) to provide a comprehensive catalogue of somatic mutations. This will be achieved through a UK-wide network of hospitals involved in a research collaboration called the OCCAMS consortium. The goal of this project is to use high quality clinical material with accurately annotated clinic-pathological, treatment and outcome data.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001048 Illumina HiSeq 2000 -
EGAD00001001394 Illumina HiSeq 2000 -
EGAD00001001960 Illumina HiSeq 2000 -
EGAD00001002218 Illumina HiSeq 2000 10
EGAD00001002241 Illumina HiSeq 2000 6
EGAD00001002259 Illumina HiSeq 2000 37
EGAD00001002260 Illumina HiSeq 2000 15
EGAD00001002689 Illumina HiSeq 2000 -
EGAD00001003292 Illumina HiSeq 2000 34
EGAD00001003580 Illumina HiSeq 2000 38
EGAD00001003839 Illumina HiSeq 2000 26
EGAD00001003900 Illumina HiSeq 2000 83
EGAD00001004007 Illumina HiSeq 2000 53
EGAD00001004021 Illumina HiSeq 2000 32
EGAD00001004028 Illumina HiSeq 2000 -
EGAD00001004029 Illumina HiSeq 2000 86
EGAD00001004137 Illumina HiSeq 2000 -
EGAD00001004289 Illumina HiSeq 2000 Illumina MiSeq 60
EGAD00001004417 Illumina HiSeq 2000 -
EGAD00001004423 Illumina HiSeq 2000 -
EGAD00001004775 Illumina HiSeq 2000 -
EGAD00001004776 Illumina HiSeq 2000 -
EGAD00001005375 Illumina HiSeq 2000 73
EGAD00001005376 Illumina HiSeq 2000 11
EGAD00001005377 Illumina HiSeq 2000 10
EGAD00001005383 Illumina HiSeq 2000 20
EGAD00001005388 Illumina HiSeq 2000 -
EGAD00001005434 Illumina HiSeq 2000 -
EGAD00001005915 Illumina HiSeq 2000 -
EGAD00001006170 Illumina HiSeq 4000 48
EGAD00001006373 NextSeq 500 48
EGAD00001006738 Illumina HiSeq 2000 7
EGAD00001007493 HiSeq X Five Illumina HiSeq 2000 Illumina NovaSeq 6000 8
EGAD00001007496 HiSeq X Five Illumina HiSeq 2000 -
EGAD00001007785 HiSeq X Five Illumina HiSeq 2000 Illumina NovaSeq 6000 -
EGAD00001007808 Illumina HiSeq 2000 -
EGAD00001007809 Illumina HiSeq 2000 -
EGAD00001011065 unspecified 6
EGAD00001011076 Illumina HiSeq 2000 unspecified -
EGAD00001011095 HiSeq X Five Illumina HiSeq 2000 -
EGAD00001011187 HiSeq X Five Illumina HiSeq 2000 Illumina NovaSeq 6000 unspecified 63
EGAD00001011188 unspecified 170
EGAD00001011190 Illumina HiSeq 2000 unspecified 49
EGAD00001011191 HiSeq X Five Illumina HiSeq 2000 Illumina NovaSeq 6000 unspecified 42
EGAD00001011196 HiSeq X Five Illumina HiSeq 2000 Illumina NovaSeq 6000 unspecified 6
EGAD00001011269 Illumina HiSeq 2000 -
EGAD00010001822 Illumina 285
Publications Citations
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.
Nat Genet 48: 2016 1131-1141
206
The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.
Nat Genet 51: 2019 506-516
104
Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma.
Nat Commun 10: 2019 3101
20
Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Gastroenterology 158: 2020 1682-1697.e1
41
Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma.
Elife 9: 2020 e57189
11
Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma.
Nat Commun 12: 2021 1454
11
Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas.
Commun Biol 5: 2022 335
6
The transcriptional landscape of endogenous retroelements delineates esophageal adenocarcinoma subtypes.
NAR Cancer 5: 2023 zcad040
0
Comprehensive analyses of partially methylated domains and differentially methylated regions in esophageal cancer reveal both cell-type- and cancer-specific epigenetic regulation.
Genome Biol 24: 2023 193
2